Abstract:The activation of microglia and the production of cytokines are key factors contributing to progressive neurodegeneration. Despite the well-recognized neuronal programmed cell death regulated by microglial activation, the death of microglia themselves is less investigated. Nucleotide-binding oligomerization domain, leucine-rich repeat-containing X1 (NLRX1) functions as a scaffolding protein and is involved in various central nervous system diseases. In this study, we used the SM826 microglial cells to understand the role of NLRX1 in lipopolysaccharide (LPS)-induced cell death. We found LPS-induced cell death is blocked by necrostatin-1 and zVAD. Meanwhile, LPS can activate poly (ADP-ribose) polymerase-1 (PARP-1) to reduce DNA damage and induce heme oxygenase (HO)-1 expression to counteract cell death. NLRX1 silencing and PARP-1 inhibition by olaparib enhance LPS-induced SM826 microglial cell death in an additive manner. Less PARylation and higher DNA damage are observed in NLRX1-silencing cells. Moreover, LPS-induced HO-1 gene and protein expression through the p62-Keap1-Nrf2 axis are attenuated by NLRX1 silencing. In addition, the Nrf2-mediated positive feedback regulation of p62 is accordingly reduced by NLRX1 silencing. Of note, NLRX1 silencing does not affect LPS-induced cellular reactive oxygen species (ROS) production but increases mixed lineage kinase domain-like pseudokinase (MLKL) activation and cell necroptosis. In addition, NLRX1 silencing blocks bafilomycin A1-induced PARP-1 activation. Taken together, for the first time, we demonstrate the role of NLRX1 in protecting microglia from LPS-induced cell death. The underlying protective mechanisms of NLRX1 include upregulating LPS-induced HO-1 expression via Nrf2-dependent p62 expression and downstream Keap1-Nrf2 axis, mediating PARP-1 activation for DNA repair via ROS- and autophagy-independent pathway, and reducing MLKL activation.

NLRX1 Negatively Regulates TLR-Induced NF-κB Signaling by Targeting TRAF6 and IKK

LRRC14 Attenuates Toll-like Receptor-Mediated NF-κB Signaling Through Disruption of IKK Complex.

NLRC5 Negatively Regulates the NF-κB and Type I Interferon Signaling Pathways

NLRX1 Is a Multifaceted and Enigmatic Regulator of Immune System Function

NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways

NLRP11 Attenuates Toll-like Receptor Signalling by Targeting TRAF6 for Degradation Via the Ubiquitin Ligase RNF19A.

IRAK-M Mediates Toll-like Receptor/il-1R-induced NFκB Activation and Cytokine Production

Trim30 Alpha Negatively Regulates Tlr-Mediated Nf-Kappa B Activation By Targeting Tab2 And Tab3 For Degradation

TAK1 Negatively Regulates NF-κB and P38 MAP Kinase Activation in Gr-1+CD11b+ Neutrophils.

Modulation of Toll–interleukin 1 receptor mediated signaling

E3 ligase RNF99 negatively regulates TLR-mediated inflammatory immune response via K48-linked ubiquitination of TAB2

TRIM30α negatively regulates TLR-mediated NF-κB activation by targeting TAB2 and TAB3 for degradation

NLRX1 Inhibits LPS-Induced Microglial Death via Inducing p62-Dependent HO-1 Expression, Inhibiting MLKL and Activating PARP-1

Enhanced TLR-induced NF-κB Signaling and Type I Interferon Responses in NLRC5 Deficient Mice

RNF144B inhibits LPS-induced inflammatory responses via binding TBK1

Cutting Edge: TRAF6 Mediates TLR/IL-1R Signaling–Induced Nontranscriptional Priming of the NLRP3 Inflammasome

USP18 negatively regulates NF-κB signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms

The E3 Ligase RNF34 is a Novel Negative Regulator of the NOD1 Pathway

NLRX1 knockout aggravates lipopolysaccharide (LPS)-induced heart injury and attenuates the anti-LPS cardioprotective effect of CYP2J2/11,12-EET by enhancing activation of NF-κB and NLRP3 inflammasome

WW domain containing E3 ubiquitin protein ligase 1 (WWP1) negatively regulates TLR4-mediated TNF-α and IL-6 production by proteasomal degradation of TNF receptor associated factor 6 (TRAF6)

Focus on negatively regulated NLRs in inflammation and cancer